Experian posts seven per cent rise in Q4 organic growth revenue
Information services company Experian has posted a rise in revenue for the three months to December 31st, during which time total revenue from continuing activities increased by seven per cent at constant exchange rates.
Information services company Experian has posted a rise in revenue for the three months to December 31st, during which time total revenue from continuing activities increased by seven per cent at constant exchange rates.
At actual exchange rates, total revenue from continuing activities increased by 5.0%, with the difference mainly reflecting depreciation of the Brazilian Real relative to the US dollar. Group organic revenue growth was 7.0% year-on-year.
Don Robert, Chief Executive Officer of Experian, said: "We are pleased with the progress made in the third quarter, with total and organic revenue growth of 7.0%, at constant exchange rates. We delivered widespread growth demonstrating the breadth of our portfolio and continued successful execution of our growth strategy, helping us to withstand ongoing pressures in the global economy.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"Looking ahead, for the full year we expect organic growth to be to high single-digit, with organic growth in the second half similar to our third quarter results. We also reiterate our full year expectations of modest margin improvement at constant currency and to convert at least 90% of EBIT [earnings before interest and tax] into operating cash."
MF
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published
-
Will the Autumn Budget impact investment markets?
Keir Starmer has warned the Autumn Budget will be “painful”. Will it impact investment markets and should you tweak your portfolio before 30 October?
By Katie Williams Published